Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update

Key Points

• Avalo Therapeutics experienced a **264.2% increase** in short interest in September, with 202,500 shares sold short, indicating increased market skepticism about the company's stock.
• The company's stock price **increased by 0.9%** to **$13.08**, with a trading volume surpassing its average, reflecting growing investor interest.
• Analysts maintain a **positive outlook** with a consensus "Buy" rating and an average price target of **$31.67**, indicating potential upside for investors.

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 202,500 shares, an increase of 264.2% from the August 31st total of 55,600 shares. Currently, 1.9% of the shares of the stock are sold short. Based on an average trading volume of 233,600 shares, the short-interest ratio is presently 0.9 days. Based on an average trading volume of 233,600 shares, the short-interest ratio is presently 0.9 days. Currently, 1.9% of the shares of the stock are sold short.

Avalo Therapeutics Stock Up 0.9%

AVTX traded up $0.12 during trading hours on Thursday, reaching $13.08. The company's stock had a trading volume of 190,692 shares, compared to its average volume of 152,744. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $16.00. The company's 50-day moving average is $9.75 and its 200-day moving average is $6.76.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($1.92) earnings per share for the quarter, missing analysts' consensus estimates of ($1.43) by ($0.49). As a group, research analysts expect that Avalo Therapeutics will post -19.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Nantahala Capital Management LLC bought a new position in shares of Avalo Therapeutics during the 1st quarter valued at about $7,209,000. Bank of America Corp DE boosted its holdings in shares of Avalo Therapeutics by 7,066.8% during the second quarter. Bank of America Corp DE now owns 406,571 shares of the company's stock worth $2,029,000 after purchasing an additional 400,898 shares during the period. RWA Wealth Partners LLC bought a new stake in shares of Avalo Therapeutics in the first quarter worth about $2,505,000. Affinity Asset Advisors LLC grew its stake in shares of Avalo Therapeutics by 19.3% in the first quarter. Affinity Asset Advisors LLC now owns 657,154 shares of the company's stock worth $5,264,000 after purchasing an additional 106,389 shares during the last quarter. Finally, Velan Capital Investment Management LP grew its stake in shares of Avalo Therapeutics by 38.4% in the second quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company's stock worth $773,000 after purchasing an additional 43,000 shares during the last quarter. Institutional investors and hedge funds own 87.06% of the company's stock.

Analysts Set New Price Targets

AVTX has been the subject of several recent research reports. Cowen initiated coverage on shares of Avalo Therapeutics in a research note on Friday, September 5th. They set a "buy" rating for the company. Cantor Fitzgerald assumed coverage on shares of Avalo Therapeutics in a research note on Friday, August 15th. They set an "overweight" rating for the company. HC Wainwright upped their price target on shares of Avalo Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, September 17th. BTIG Research reiterated a "buy" rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a research note on Monday. Finally, TD Cowen began coverage on shares of Avalo Therapeutics in a research note on Friday, September 5th. They issued a "buy" rating on the stock. Nine equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $31.67.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.